Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaophthalmol.2023.4215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Laser-Induced Chorioretinal Anastomosis in Neurofibromatosis Type 1.
JAMA Ophthalmol
November 2023
Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.
Benefits of a Laser Chorioretinal Anastomosis Plus Ranibizumab vs Ranibizumab Alone for Central Retinal Vein Occlusion: 4-Year Results.
Am J Ophthalmol
August 2023
From the Centre for Ophthalmology and Visual Science (I.L.M., L.A.S., F.K.C., D.A.M., P.G.S.), Lions Eye Institute, University of Western Australia, Perth, Australia; Centre for Eye Research Australia (P.G.S.), University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Australia.
Purpose: To evaluate what clinical gains can be achieved over conventional treatment with ranibizumab alone for central retinal vein occlusion (CRVO) when causal pathology is additionally addressed successfully with a laser-induced chorio-retinal anastomosis (L-CRA).
Design: Two-year extension of prospective, randomized controlled clinical trial.
Methods: A total of 58 patients with macular edema secondary to CRVO were randomized 1:1 to receive either an L-CRA (n = 29) or sham procedure (n = 29) at baseline and then monthly intravitreal ranibizumab 0.
Animal Models of Choroidal Neovascularization: A Systematic Review.
Invest Ophthalmol Vis Sci
August 2022
Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Purpose: Animal models of choroidal neovascularization (CNV) are extensively used to characterize the pathophysiology of chorioretinal diseases with CNV formation and to evaluate novel treatment strategies. This systematic review aims to give a detailed overview of contemporary animal models of CNV.
Methods: A systematic search was performed in PubMed and EMBASE from November 20, 2015, to November 20, 2020, for mammalian animal models of CNV.
Laser-Induced Chorioretinal Anastomosis Can Be an Effective Permanent Treatment for Central Retinal Vein Occlusion.
Asia Pac J Ophthalmol (Phila)
January 2022
International Eye Research Institute of The Chinese University of Hong Kong (Shenzhen), Shenzhen, China.
Functional benefits of a chorioretinal anastomosis at 2 years in eyes with a central retinal vein occlusion treated with ranibizumab compared with ranibizumab monotherapy.
BMJ Open Ophthalmol
March 2021
Centre for Eye Research Australia, Melbourne, Victoria, Australia.
Objective: To evaluate the functional benefits (best corrected visual acuity (BCVA), central subfield thickness, injection loads, central venous pressure (CVP)) of a laser-induced chorioretinal anastomosis (L-CRA) in patients with central retinal vein occlusion (CRVO) treated with ranibizumab compared with ranibizumab monotherapy.
Methods And Analysis: This is a post-hoc analysis of the 2-year randomised ranibizumab plus L-CRA for CRVO trial. Twenty-four patients (82.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!